Study: Omicron evades some but not all monoclonal antibodies

Several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the omicron variant now sweeping across the United States, researchers reported Jan. 19 in the journal Nature Medicine.

SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex

Omicron may sideline two leading drugs against COVID-19

The ability of therapeutic monoclonal antibodies to neutralize SARS-CoV-2 Omicron BA.2 variant

Why omicron is more infectious than other coronavirus variants

New Study Adds More Evidence for Omicron Immune Evasion

Newest Omicron subvariants can evade boosters, antibody therapies

Viruses, Free Full-Text

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Frontiers Impact of mAb-induced A475V substitution on viral fitness and antibody neutralization of SARS-CoV-2 omicron variants in the presence of monoclonal antibodies and human convalescent sera

Immune Escape Mechanisms of SARS-CoV-2 Delta and Omicron Variants against Two Monoclonal Antibodies That Received Emergency Use Authorization

A COVID treatment wanes: New variants outsmart most monoclonal antibodies : Shots - Health News : NPR

COVID, Free Full-Text

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies - eBioMedicine

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

FDA Limits Use of Monoclonal Antibodies to Treat COVID-19